What Is the Evidence Supporting Neoadjuvant Immunotherapy in Early-Stage NSCLC?
b'Guest: Patrick Forde, M.B.B.Ch.
\\n\\n\\n \\n
This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.
'